Skip to main content

Dana-Farber Research Publication, 03.01.2024

Welcome to Dana-Farber's Research News

View Archive Newsletters

March 01, 2023

This twice-monthly newsletter highlights the research endeavors at Dana-Farber Cancer Institute, noting recently published papers available from PubMed where Dana-Farber faculty are listed as first or senior authors. If you are a Dana-Farber faculty member and you think your paper is missing from Research News, please let us know at: Michael_buller@dfci.harvard.edu.

 

Blood

Ibrutinib and Venetoclax as Primary Therapy in Symptomatic, Treatment-Naïve Waldenström Macroglobulinemia

Castillo JJ, Branagan AR, Sermer D, Flynn CA, Meid K, Little M, Stockman K, White T, Canning A, Guerrera ML, Kofides A, Liu S, Liu X, Richardson K, Tsakmaklis N, Patterson CJ, Hunter ZR, Treon SP, Sarosiek S

Concurrent Bruton tyrosine kinase and BCL2 inhibition has not yet been investigated in Waldenström macroglobulinemia (WM). We performed an investigator-initiated trial of ibrutinib and venetoclax in symptomatic treatment-naïve patients with MYD88-mutated WM. Patients received ibrutinib 420 mg once daily (cycle 1), followed by a ramp-up of venetoclax to 400 mg daily (cycle 2). The combination was then administered for 22 additional 4-week cycles. The attainment of very good partial response (VGPR) was the primary end point. Forty-five patients were enrolled in this study. The median baseline characteristics were as follows: age 67 years, serum IgM 43 g/L, and hemoglobin 102 g/L. Seventeen patients (38%) carried CXCR4 mutations. Nineteen patients (42%) achieved VGPR. Grade 3 or higher adverse events included neutropenia (38%), mucositis (9%), and tumor lysis syndrome (7%). Atrial fibrillation occurred in 3 (9%), and ventricular arrhythmia in 4 (9%) patients that included 2 grade 5 events. With a median follow-up of 24.4 months, the 24-month progression-free survival (PFS) and overall survival (OS) rates were 76% and 96%, respectively, and were not impacted by CXCR4 mutations. The median time on therapy was 10.2 months, and the median time after the end of therapy (EOT) was 13.3 months. Eleven of the 12 progression events occurred after EOT, and the 12-month PFS rates after EOT were 79%; 93% if VGPR was attained, and 69% for other patients (P = .12). Ibrutinib and venetoclax induced high VGPR rates and durable responses after EOT, although they were associated with a higher-than-expected rate of ventricular arrhythmia in patients with WM, leading to early study treatment termination. This trial was registered at www.clinicaltrials.gov as #NCT04273139.


 

Blood

Three-Year Follow-Up Analysis of Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA-5)

Jacobson CA

Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory (R/R) follicular lymphoma (FL). Approval was supported by the phase 2, multicenter, single-arm ZUMA-5 study of axi-cel for patients with R/R indolent non-Hodgkin lymphoma (iNHL; N = 104), including FL and marginal zone lymphoma (MZL). In the primary analysis (median follow-up, 17.5 months), the overall response rate (ORR) was 92% (complete response rate, 74%). Here, we report long-term outcomes from ZUMA-5. Eligible patients with R/R iNHL after ?2 lines of therapy underwent leukapheresis, followed by lymphodepleting chemotherapy and axi-cel infusion (2 × 106 CAR T cells per kg). The primary end point was ORR, assessed in this analysis by investigators in all enrolled patients (intent-to-treat). After median follow-up of 41.7 months in FL (n = 127) and 31.8 months in MZL (n = 31), ORR was comparable with that of the primary analysis (FL, 94%; MZL, 77%). Median progression-free survival was 40.2 months in FL and not reached in MZL. Medians of overall survival were not reached in either disease type. Grade ?3 adverse events of interest that occurred after the prior analyses were largely in recently treated patients. Clinical and pharmacokinetic outcomes correlated negatively with recent exposure to bendamustine and high metabolic tumor volume. After 3 years of follow-up in ZUMA-5, axi-cel demonstrated continued durable responses, with very few relapses beyond 2 years, and manageable safety in patients with R/R iNHL. The ZUMA-5 study was registered at www.clinicaltrials.gov as #NCT03105336.


 

Cell

Inherited Blood Cancer Predisposition Through Altered Transcription Elongation

Zhao J, Cato LD, Arora UP, Bao EL, Bryant SC, Jia Y, Goldman SR, Armstrong SA, Sankaran VG

Despite advances in defining diverse somatic mutations that cause myeloid malignancies, a significant heritable component for these cancers remains largely unexplained. Here, we perform rare variant association studies in a large population cohort to identify inherited predisposition genes for these blood cancers. CTR9, which encodes a key component of the PAF1 transcription elongation complex, is among the significant genes identified. The risk variants found in the cases cause loss of function and result in a ?10-fold increased odds of acquiring a myeloid malignancy. Partial CTR9 loss of function expands human hematopoietic stem cells (HSCs) by increased super elongation complex-mediated transcriptional activity, which thereby increases the expression of key regulators of HSC self-renewal. By following up on insights from a human genetic study examining inherited predisposition to the myeloid malignancies, we define a previously unknown antagonistic interaction between the PAF1 and super elongation complexes. These insights could enable targeted approaches for blood cancer prevention.


 

Gastroenterology

A Novel Approach for Pancreas Transcriptomics Reveals the Cellular Landscape in Homeostasis and Acute Pancreatitis

Aney KJ, Jeong WJ, Chen E, Wang A, Koak P, Dougan SK, Nissim S

BACKGROUND & AIMS: Acinar cells produce digestive enzymes that impede transcriptomic characterization of the exocrine pancreas. Thus, single-cell RNA-sequencing (scRNA-seq) studies of the pancreas underrepresent acinar cells relative to histological expectations, and a robust approach to capture pancreatic cell responses in disease states is needed. We sought to innovate a method that overcomes these challenges to accelerate study of the pancreas in health and disease.

METHODS: We introduce FixNCut, a scRNA-seq approach where tissue is reversibly fixed with dithiobis(succinimidyl propionate) prior to dissociation and single-cell preparation. We apply FixNCut to an established mouse model of acute pancreatitis, validate findings using GeoMx whole transcriptome atlas (WTA) profiling, and integrate our data with prior studies to benchmark our method in both mouse and human pancreas datasets.

RESULTS: FixNCut achieves unprecedented definition of challenging pancreatic cells including acinar and immune populations in homeostasis and acute pancreatitis, and identifies changes in all major cell types during injury and recovery. We define the acinar transcriptome during homeostasis and acinar-to-ductal metaplasia and establish a unique gene set to measure deviation from normal acinar identity. We characterize pancreatic immune cells, and analysis of T-cell subsets reveals a polarization of the homeostatic pancreas towards type-2 immunity. We report immune responses during acute pancreatitis and recovery, including early neutrophil infiltration, expansion of dendritic cell subsets, and a substantial shift in the transcriptome of macrophages due to both resident macrophage activation and monocyte infiltration.

CONCLUSIONS: FixNCut preserves pancreatic transcriptomes to uncover novel cell states during homeostasis and following pancreatitis, establishing a broadly applicable approach and reference atlas for study of pancreas biology and disease.


 

Gastroenterology

A Randomized Trial of Two Remote Healthcare Delivery Models on the Uptake of Genetic Testing and Impact on Patient-Reported Psychological Outcomes in Families with Pancreatic Cancer: The Genetic Education, Risk Assessment, and Testing (GENERATE) Study

Rodriguez NJ, Furniss CS, Yurgelun MB, Ukaegbu C, Fortes I, Caruso A, Schwartz AN, Stopfer JE, Underhill-Blazey M, Uno H, Horiguchi M, Garber JE, Syngal S

BACKGROUND AND AIMS: Genetic testing uptake for cancer susceptibility in family members of cancer patients is suboptimal. Among relatives of pancreatic ductal adenocarcinoma (PDAC) patients, The GENetic Education, Risk Assessment, and TEsting (GENERATE) study evaluated two online genetic education/testing delivery models and their impact on patient-reported psychological outcomes (PRPOs).

METHODS: Eligible participants had ?1 first-degree relative with PDAC, or ?1 first-/second-degree relative with PDAC with a known pathogenic germline variant in one of thirteen PDAC predisposition genes. Participants were randomized by family, between 5/8/2019-6/1/2021. Arm 1 participants underwent a remote interactive telemedicine session and online genetic education. Arm 2 participants were offered online genetic education only. All participants were offered germline testing. The primary outcome was genetic testing uptake, compared by permutation tests and mixed-effects logistic regression models. We hypothesized that Arm 1 participants would have a higher genetic testing uptake than Arm 2. Validated surveys were administered to assess patient-reported anxiety, depression, and cancer worry at baseline and 3-months post-intervention.

RESULTS: 424 families were randomized, including 601 participants (n=296 Arm 1; n=305 Arm 2), 90% of whom completed genetic testing (Arm 1 (87%); Arm 2 (93%), p=0.014). Arm 1 participants were significantly less likely to complete genetic testing compared to Arm 2 (adjusted ratio (Arm1/Arm2) 0.90, 95% confidence interval 0.78-0.98). Among participants who completed PRPO questionnaires (Arm 1 (n=194); Arm 2 (n=206)), the intervention did not impact mean anxiety, depression or cancer worry scores.

CONCLUSIONS: Remote genetic education and testing can be a successful and complementary option for delivering genetics care.


 

Journal of Clinical Oncology

Crenolanib and Intensive Chemotherapy in Adults with Newly Diagnosed FLT3-Mutated AML

Stone RM

PURPOSE: Crenolanib is a second-generation tyrosine kinase inhibitor with activity against FLT3-ITD- and TKD-mutant AML. We conducted a trial of crenolanib plus intensive chemotherapy in adults with newly diagnosed FLT3-mutant AML.

METHODS: Eligible patients were 18 years and older. Induction chemotherapy consisted of cytarabine (100 mg/m2) continuous infusion on days 1-7 and anthracycline (daunorubicin 60-90 mg/m2 or idarubicin 12 mg/m2, once daily) on days 1-3 followed by consolidation with high-dose cytarabine (1-3 g/m2 twice daily on days 1, 3, 5) and/or allogeneic transplant. Crenolanib (100 mg thrice a day) was given from day 9 until 72 hours before the next cycle, after consolidation, and for 12 months after consolidation or transplant.

RESULTS: Forty-four patients (median age, 57; range, 19-75 years) were enrolled. Thirty-six had FLT3-ITD, and 11 had FLT3-TKD mutations. European LeukemiaNet 2017 disease risk was favorable in 34%, intermediate in 30%, and adverse in 36%. The overall response rate was 86% (complete remission [CR], 77%; CR with incomplete count recovery [CRi], 9%): 90% in patients 60 years and younger and 80% in older patients. Measurable residual disease-negative CR/CRi rates were 89% and 45%, respectively. With a 45-month follow-up, median overall survival has not been reached and the median event-free survival was 44.7 months. Among younger patients, the estimated 3-year survival was 71.4% with 15% cumulative incidence of relapse. Treatment-related serious adverse events included febrile neutropenia, diarrhea, and nausea. The median time to platelets ?100,000/µL and absolute neutrophil count ?1,000/µL during induction was 29 and 32 days, respectively. No new FLT3-mutant clones were detected at relapse in patients completing consolidation.

CONCLUSION: Crenolanib plus intensive chemotherapy in adults with newly diagnosed FLT3-mutant AML results in high rate of deep responses and long-term survival with acceptable toxicity. A randomized trial of crenolanib versus midostaurin plus chemotherapy in younger patients is ongoing.


 

Journal of Clinical Oncology

Everolimus for Children with Recurrent or Progressive Low-Grade Glioma: Results from the Phase II PNOC001 Trial

Haas-Kogan DA, Liu KX

PURPOSE: The PNOC001 phase II single-arm trial sought to estimate progression-free survival (PFS) associated with everolimus therapy for progressive/recurrent pediatric low-grade glioma (pLGG) on the basis ofphosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway activation as measured by phosphorylated-ribosomal protein S6 and to identify prognostic and predictive biomarkers.

PATIENTS AND METHODS: Patients, age 3-21 years, with progressive/recurrent pLGG received everolimus orally, 5 mg/m2 once daily. Frequency of driver gene alterations was compared among independent pLGG cohorts of newly diagnosed and progressive/recurrent patients. PFS at 6 months (primary end point) and median PFS (secondary end point) were estimated for association with everolimus therapy.

RESULTS: Between 2012 and 2019, 65 subjects with progressive/recurrent pLGG (median age, 9.6 years; range, 3.0-19.9; 46% female) were enrolled, with a median follow-up of 57.5 months. The 6-month PFS was 67.4% (95% CI, 60.0 to 80.0) and median PFS was 11.1 months (95% CI, 7.6 to 19.8). Hypertriglyceridemia was the most common grade ?3 adverse event. PI3K/AKT/mTOR pathway activation did not correlate with clinical outcomes (6-month PFS, active 68.4% v nonactive 63.3%; median PFS, active 11.2 months v nonactive 11.1 months; P = .80). Rare/novel KIAA1549::BRAF fusion breakpoints were most frequent in supratentorial midline pilocytic astrocytomas, in patients with progressive/recurrent disease, and correlated with poor clinical outcomes (median PFS, rare/novel KIAA1549::BRAF fusion breakpoints 6.1 months v common KIAA1549::BRAF fusion breakpoints 16.7 months; P < .05). Multivariate analysis confirmed their independent risk factor status for disease progression in PNOC001 and other, independent cohorts. Additionally, rare pathogenic germline variants in homologous recombination genes were identified in 6.8% of PNOC001 patients.

CONCLUSION: Everolimus is a well-tolerated therapy for progressive/recurrent pLGGs. Rare/novel KIAA1549::BRAF fusion breakpoints may define biomarkers for progressive disease and should be assessed in future clinical trials.


 

Journal of Clinical Oncology

ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma

Arrillaga-Romany I, Batchelor T, Wen PY

PURPOSE: Histone 3 (H3) K27M-mutant diffuse midline glioma (DMG) has a dismal prognosis with no established effective therapy beyond radiation. This integrated analysis evaluated single-agent ONC201 (dordaviprone), a first-in-class imipridone, in recurrent H3 K27M-mutant DMG.

METHODS: Fifty patients (pediatric, n = 4; adult, n = 46) with recurrent H3 K27M-mutant DMG who received oral ONC201 monotherapy in four clinical trials or one expanded access protocol were included. Eligible patients had measurable disease by Response Assessment in Neuro-Oncology (RANO) high-grade glioma (HGG) criteria and performance score (PS) ?60 and were ?90 days from radiation; pontine and spinal tumors were ineligible. The primary end point was overall response rate (ORR) by RANO-HGG criteria. Secondary end points included duration of response (DOR), time to response (TTR), corticosteroid response, PS response, and ORR by RANO low-grade glioma (LGG) criteria. Radiographic end points were assessed by dual-reader, blinded independent central review.

RESULTS: The ORR (RANO-HGG) was 20.0% (95% CI, 10.0 to 33.7). The median TTR was 8.3 months (range, 1.9-15.9); the median DOR was 11.2 months (95% CI, 3.8 to not reached). The ORR by combined RANO-HGG/LGG criteria was 30.0% (95% CI, 17.9 to 44.6). A ?50% corticosteroid dose reduction occurred in 7 of 15 evaluable patients (46.7% [95% CI, 21.3 to 73.4]); PS improvement occurred in 6 of 34 evaluable patients (20.6% [95% CI, 8.7 to 37.9]). Grade 3 treatment-related treatment-emergent adverse events (TR-TEAEs) occurred in 20.0% of patients; the most common was fatigue (n = 5; 10%); no grade 4 TR-TEAEs, deaths, or discontinuations occurred.

CONCLUSION: ONC201 monotherapy was well tolerated and exhibited durable and clinically meaningful efficacy in recurrent H3 K27M-mutant DMG.


 

Journal of Clinical Oncology

Understanding Adjuvant Therapy for Upper Tract Urothelial Carcinoma

Berg SA

Despite decades of research, the oncology community has faced significant challenges in establishing robust evidence for the role of perioperative chemotherapy for the treatment of urothelial cancer of the bladder. Although early adjuvant therapy trials suggested a potential benefit, limitations in sample size and premature closures because of poor patient accrual hampered their interpretation. Two randomized studies, however, demonstrated a survival benefit with neoadjuvant cisplatin-based chemotherapy followed by definitive local therapy, leading to its incorporation into clinical practice guidelines. Implementation of perioperative cisplatin-based chemotherapy has been limited by the advanced age and comorbidities often observed in patients with bladder cancer, ultimately restricting its applicability to a subset of patients.


 

Journal of the National Cancer Institute

Are Linchpin Oncologists Keeping the Wheels from Falling Off Cancer Care?

Manz CR, Barnett ML

Medical, radiation, and surgical oncologists, like other clinicians, are practicing in increasingly complex professional networks. Expanding sub specialization, increased use of advanced practice clinicians, and an increasingly part-time work force all contribute to a more interconnected, yet diffuse health-care system than in previous decades. This complexity can be bewildering to patients and physicians. Further complicating the matter is the tremendous variation across the country in the structure of oncology care networks. Particularly in resource-limited settings, clinicians specializing in medical, radiation, and surgical oncology may be in short supply, which could constrain timely patient access to more advanced treatment. The connections of these more isolated oncology clinicians to other clinicians, which constitute a complex and intricate network of referrals, could also be quite important for ensuring high-quality, multidisciplinary care that optimizes patient outcomes.


 

Journal of the National Cancer Institute

Association of N-Terminal Pro-Brain Natriuretic Peptide with Survival Among US Cancer Survivors

Cao C, Nohria A, Mayer EL, Partridge AH, Ligibel JA

BACKGROUND: N-terminal pro-brain natriuretic peptide (NT-proBNP) is a cardiac biomarker associated with the risk of heart failure and death in the general population but has not been explored in cancer survivors.

METHODS: Using a US nationally representative sample of adults ?20?years from the National Health and Nutrition Examination Survey from 1999 to 2004, this study compared NT-proBNP levels between non-cancer adults (n?=?12574) and cancer survivors (n?=?787) and examined the association of NT-proBNP with all-cause and cause-specific mortality among cancer survivors.

RESULTS: Cancer survivors had higher NT-proBNP levels than non-cancer adults (median: 125.4 [IQR, 52.4 to 286.0] vs 43.2 [IQR, 20.3-95.0]). In particular, survivors of breast, prostate, and colorectal cancers had higher NT-proBNP levels than non-cancer adults (multivariable-adjusted P<.05). 471 survivors died (cancer: 141; cardiac disease: 95) during a median follow-up of 13.4?years (9,393 person-years). Among cancer survivors, higher NT-proBNP levels were statistically associated with increased risks of all-cause (HR, 1.31 [95% CI, 1.18-1.46]) and cardiac (HR, 1.55 [95% CI, 1.21-2.00) mortality but not with death due to cancer (HR, 1.10 [95% CI, 0.92-1.32]). Higher NT-proBNP levels were associated with elevated overall mortality in survivors of prostate (HR, 1.45 [95% CI, 1.17-1.79]) and colorectal (HR, 1.78 [95% 1.12-2.85]) cancers (P-interaction?=?0.169). Non-linear dose-response relationships were observed between NT-proBNP and mortality, with statistically significant relationships emerging above 125?pg/ml.

CONCLUSIONS: Cancer survivors had higher NT-proBNP than non-cancer adults, and elevated NT-proBNP levels were associated with higher risks of all-cause and cardiac mortality in cancer survivors.


 

Lancet Oncology

Activity and Safety of Enobosarm, a Novel, Oral, Selective Androgen Receptor Modulator, in Androgen Receptor-Positive, Oestrogen Receptor-Positive, and HER2-Negative Advanced Breast Cancer (Study G200802): A Randomised, Open-Label, Multicentre, Multinational, Parallel Design, Phase 2 Trial

Overmoyer B

BACKGROUND: The androgen receptor is a tumour suppressor in oestrogen receptor-positive breast cancer. The activity and safety of enobosarm, an oral selective androgen receptor modulator, was evaluated in women with oestrogen receptor (ER)-positive, HER2-negative, and androgen receptor (AR)-positive disease.

METHODS: Women who were postmenopausal (aged ?18 years) with previously treated ER-positive, HER2-negative, locally advanced or metastatic breast cancer with an Eastern Cooperative Oncology Group performance status of 0-2 were enrolled in a randomised, open-label, multicentre, multinational, parallel design, phase 2 trial done at 35 cancer treatment centres in nine countries. Participants were stratified on the setting of immediately preceding endocrine therapy and the presence of bone-only metastasis and randomly assigned (1:1) to 9 mg or 18 mg oral enobosarm daily using an interactive web response system. The primary endpoint was clinical benefit rate at 24 weeks in those with centrally confirmed AR-positive disease (ie, the evaluable population). This trial is registered with ClinicalTrials.gov (NCT02463032).

FINDINGS: Between Sept 10, 2015, and Nov 28, 2017, 136 (79%) of 172 patients deemed eligible were randomly assigned to 9 mg (n=72) or 18 mg (n=64) oral enobosarm daily. Of these 136 patients, 102 (75%) patients formed the evaluable population (9 mg, n=50; 18 mg, n=52). The median age was 60·5 years (IQR 52·3-69·3) in the 9 mg group and 62·5 years (54·0-69·3) in the 18 mg group. The median follow-up was 7·5 months (IQR 2·9-14·1). At 24 weeks, 16 (32%, 95% CI 20-47) of 50 in the 9 mg group and 15 (29%, 17-43) of 52 in the 18 mg group had clinical benefit. Six (8%) of 75 patients who received 9 mg and ten (16%) of 61 patients who received 18 mg had grade 3 or grade 4 drug-related adverse events, most frequently increased hepatic transaminases (three [4%] of 75 in the 9 mg group and two [3%] of 61 in the 18 mg group), hypercalcaemia (two [3%] and two [3%]), and fatigue (one [1%] and two [3%]). Four deaths (one in the 9 mg group and three in the 18 mg group) were deemed unrelated to the study drug.

INTERPRETATION: Enobosarm has anti-tumour activity in patients with ER-positive, HER2-negative advanced breast cancer, showing that AR activation can result in clinical benefit, supporting further clinical investigation of selective AR activation strategies for the treatment of AR-positive, ER-positive, HER2-negative advanced breast cancer.

FUNDING: GTx.


 

Nature Chemical Biology

Antibody Discovery Identifies Regulatory Mechanisms of Protein Arginine Deiminase

Zhou X

Unlocking the potential of protein arginine deiminase 4 (PAD4) as a drug target for rheumatoid arthritis requires a deeper understanding of its regulation. In this study, we use unbiased antibody selections to identify functional antibodies capable of either activating or inhibiting PAD4 activity. Through cryogenic-electron microscopy, we characterized the structures of these antibodies in complex with PAD4 and revealed insights into their mechanisms of action. Rather than steric occlusion of the substrate-binding catalytic pocket, the antibodies modulate PAD4 activity through interactions with allosteric binding sites adjacent to the catalytic pocket. These binding events lead to either alteration of the active site conformation or the enzyme oligomeric state, resulting in modulation of PAD4 activity. Our study uses antibody engineering to reveal new mechanisms for enzyme regulation and highlights the potential of using PAD4 agonist and antagonist antibodies for studying PAD4-dependency in disease models and future therapeutic development.


 

Nature Communications

Epigenetic Regulation of CD38/CD48 by KDM6A Mediates NK Cell Response in Multiple Myeloma

Liu J, Wen K, Liu N, Liu Y, Wu G, Song TY, Kurata K, Penailillo J, Morelli E, Wang T, Gulla A, Tai YT, Munshi N, Richardson P, Carrasco R, Hideshima T, Anderson KC

Anti-CD38 monoclonal antibodies like Daratumumab (Dara) are effective in multiple myeloma (MM); however, drug resistance ultimately occurs and the mechanisms behind this are poorly understood. Here, we identify, via two in vitro genome-wide CRISPR screens probing Daratumumab resistance, KDM6A as an important regulator of sensitivity to Daratumumab-mediated antibody-dependent cellular cytotoxicity (ADCC). Loss of KDM6A leads to increased levels of H3K27me3 on the promoter of CD38, resulting in a marked downregulation in CD38 expression, which may cause resistance to Daratumumab-mediated ADCC. Re-introducing CD38 does not reverse Daratumumab-mediated ADCC fully, which suggests that additional KDM6A targets, including CD48 which is also downregulated upon KDM6A loss, contribute to Daratumumab-mediated ADCC. Inhibition of H3K27me3 with an EZH2 inhibitor resulted in CD38 and CD48 upregulation and restored sensitivity to Daratumumab. These findings suggest KDM6A loss as a mechanism of Daratumumab resistance and lay down the proof of principle for the therapeutic application of EZH2 inhibitors, one of which is already FDA-approved, in improving MM responsiveness to Daratumumab.


 

Nature Communications

Matrin3 Mediates Differentiation Through Stabilizing Chromatin Loop-Domain Interactions and YY1 Mediated Enhancer-Promoter Interactions

Liu T, Zhu Q, Kai Y, Bingham T, Cha HJ, Mehta S, Schlaeger TM, Yuan GC, Orkin SH

Although emerging evidence indicates that alterations in proteins within nuclear compartments elicit changes in chromosomal architecture and differentiation, the underlying mechanisms are not well understood. Here we investigate the direct role of the abundant nuclear complex protein Matrin3 (Matr3) in chromatin architecture and development in the context of myogenesis. Using an acute targeted protein degradation platform (dTAG-Matr3), we reveal the dynamics of development-related chromatin reorganization. High-throughput chromosome conformation capture (Hi-C) experiments revealed substantial chromatin loop rearrangements soon after Matr3 depletion. Notably, YY1 binding was detected, accompanied by the emergence of novel YY1-mediated enhancer-promoter loops, which occurred concurrently with changes in histone modifications and chromatin-level binding patterns. Changes in chromatin occupancy by Matr3 also correlated with these alterations. Overall, our results suggest that Matr3 mediates differentiation through stabilizing chromatin accessibility and chromatin loop-domain interactions, and highlight a conserved and direct role for Matr3 in maintenance of chromosomal architecture.


 

Science Immunology

Throwing IL-1? for a Loop

Jacobs N, Griffin GK

The lncRNA AMANZI exerts cis-regulatory control of IL-1?-mediated inflammation.


 

American Journal of Human Genetics

A Comprehensive Analysis of Clinical and Polygenic Germline Influences on Somatic Mutational Burden

Taraszka K, Groha S, Gusev A


 

Annals of Surgical Oncology

ASO Visual Abstract: Racial and Ethnic Disparities in Outcomes after Breast-Conserving Therapy and Endocrine Therapy for DCIS-A Post Hoc Analysis of the NSABP B-35 Randomized, Clinical Trial

Kantor O, King TA, Jones A, Glass C, Leonard SJ, Ogayo ER, Mayer EL, Freedman RA, Mittendorf EA


 

Annals of Surgical Oncology

Opportunities for De-Escalation of Axillary Surgery in Patients with Ductal Carcinoma in Situ with Microinvasion

Hersh EH, Minami CA, Weiss A, King TA


 

Annals of Surgical Oncology

Trends in Locoregional Therapy in Older Women with Early-Stage Hormone Receptor-Positive Breast Cancer by Frailty and Life Expectancy

Minami CA, Jin G, Freedman RA, Schonberg MA, King TA, Mittendorf EA


 

Annual Review of Biochemistry

Signaling from RAS to RAF: The Molecules and Their Mechanisms

Jeon H, Tkacik E, Eck MJ


 

Annual Review of Physiology

The Role of the Microbiome in the Etiopathogenesis of Colon Cancer

El Tekle G, Andreeva N, Garrett WS


 

Bioinformatics

Conumee 2.0: Enhanced Copy-Number Variation Analysis from DNA Methylation Arrays for Humans and Mice

Daenekas B, Boniolo F, Stefan S, Benfatto S, Hovestadt V


 

Biostatistics

Uncertainty Directed Factorial Clinical Trials

Kotecha G, Trippa L


 

Blood Advances

Phase 1b Trial of Tagraxofusp in Combination with Azacitidine with or without Venetoclax in Acute Myeloid Leukemia

Lane AA, Garcia JS, Raulston EG, Garzon JL, Galinsky I, Baxter EW, Leonard R, DeAngelo DJ, Luskin MR, Reilly CR, Stahl M, Stone RM, Vedula RS, Wadleigh MM, Winer ES, Stevenson KE, Neuberg DS, Ren S, Keating J


 

Blood Advances

Systematic Evaluation of Donor-KIR/Recipient-HLA Interactions in HLA-Matched Hematopoietic Cell Transplantation for AML

Romee R, Koreth J


 

Blood Cancer Discovery

The Siren Song of Synergy

Bhola PD, Letai A


 

BMC Urology

Prostate Cancer Presentation and Management in the Middle East

Sayan M, Moningi S, Orio PF


 

Breast Cancer Research and Treatment

A Randomized Phase II Study of Metronomic Cyclophosphamide and Methotrexate (CM) with or without Bevacizumab in Patients with Advanced Breast Cancer

Mayer EL, Tayob N, Ren S, Savoie JJ, Spigel DR, Burris HA 3rd, Ryan PD, Harris LN, Winer EP, Burstein HJ


 

Cancer

Conception and Pregnancy Among Women with a Live Birth After Breast Cancer Treatment: A Survey Study of Young Breast Cancer Survivors

Sorouri K, Sella T, Loucks M, Kirkner G, Snow C, Gelber SI, Peppercorn JM, Come SE, Partridge AH


 

Cancer

Sexual Health Assessment in Women with Lung Cancer Study: Sexual Health Assessment in Women with Lung Cancer

Florez N, Kiel L, Meza K, Wei Z, Mazzola E, Franco I


 

Cancer Research Communications

Estrogen Receptor Mutations as Novel Targets for Immunotherapy in Metastatic Estrogen Receptor-Positive Breast Cancer

Goldberg J, Guerriero JL, Gross B, Rahman T, Jeselsohn R, Tolaney SM, Mittendorf EA


 

Circulation

Clonal Hematopoiesis of Indeterminate Potential with Loss of Tet2 Enhances Risk for Atrial Fibrillation Through Nlrp3 Inflammasome Activation

Lin AE, Bapat AC, Xiao L, Niroula A, Ye J, Wong WJ, Agrawal M, Hergott CB, McConkey M, Flores-Bringas P, Shkolnik V, Milan D, Natarajan P, Libby P, Ellinor PT, Ebert BL


 

Clinical Cancer Research

Overcoming Resistance in Chronic Lymphocytic Leukemia-Maybe Less Is More?

Davids MS


 

Clinical Cancer Research

PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-?B Signaling in Patients with Pancreatic Cancer

Ali LR, Lenehan PJ, Cardot-Ruffino V, Dias Costa A, Nowak JA, Wolpin BM, Abrams TA, Patel A, Clancy TE, Wang J, Mancias JD, Rahma OE, Dougan SK


 

Clinical Cancer Research

RAS/RAF Co-Mutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-Directed Therapy in Colorectal Cancer

Singh H, Sahgal P, Kapner K, Gupta H, Li YY, Cherniack AD, El Alam R, Kerfoot J, Andrews E, Lee A, Nambiar C, Hannigan AM, Remland J, Brais L, Leahy ME, Rubinson DA, Schlechter BL, Meyerson M, Kuang Y, Paweletz CP, Aguirre AJ, Perez KJ, Huffman BM, Rossi H, Abrams TA, Sicinska ET, Parikh AR, Wolpin BM, Giannakis M, Ng K, Meyerhardt JA, Hornick JL, Sethi NS, Cleary JM


 

Current Neurology and Neuroscience Reports

Updated Response Assessment in Neuro-Oncology (RANO) for Gliomas

Youssef G, Wen PY


 

Current Opinion in Biotechnology

Two in One: The Emerging Concept of Bifunctional Antibodies

Rhee K, Zhou X


 

Current Treatment Options in Oncology

One Size Fits Some: Approaching Rare Malignancies of the Urinary Tract

Berg SA, McGregor BA


 

European Journal of Cancer

Evolution of HER2 Expression Between Pre-Treatment Biopsy and Residual Disease After Neoadjuvant Therapy for Breast Cancer

Tarantino P, Ajari O, Graham N, Vincuilla J, Parker T, Hughes ME, Tayob N, Garrido-Castro AC, Morganti S, King TA, Mittendorf EA, Lin NU, Tolaney SM


 

European Urology Oncology

Stereotactic Magnetic Resonance-guided Adaptive Radiation Therapy for Localized Kidney Cancer: Early Outcomes from a Prospective Phase 1 Trial and Supplemental Cohort

Yim K, Hsu SH, Nolazco JI, Cagney D, Mak RH, D'Andrea V, Singer L, Williams C, Huynh E, Han Z, Martin N, Nguyen P, Kibel AS, Choueiri TK, Chang SL, Leeman JE


 

Gastric Cancer

Bemarituzumab as First-Line Treatment for Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Final Analysis of the Randomized Phase 2 FIGHT Trial

Enzinger PC


 

Haematologica

Isatuximab-Pomalidomide-Dexamethasone Versus Pomalidomide-Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma: Final Overall Survival Analysis

Richardson PG, Anderson KC


 

Hematology/Oncology Clinics of North America

An Overview of Cervical Cancer Prevention and Control in Latin America and the Caribbean Countries

Contreras-Chavez P, Kiel L, Florez N


 

Hematology/Oncology Clinics of North America

State of Cancer Control in South America: Challenges and Advancement Strategies

Abuali I, Florez N


 

Immunity

The B7:CD28 Family and Friends: Unraveling Coinhibitory Interactions

Burke KP, Chaudhri A, Freeman GJ, Sharpe AH


 

International Journal of Radiation Oncology, Biology, Physics

Can Extreme Dose Escalation with External Beam Radiation Therapy and Low-Dose-Rate Brachytherapy Boost Obviate the Need for Long-Term Androgen Deprivation Therapy in Patients with High-Risk Localized Prostate Cancer?

King MT, Orio PF, D'Amico AV


 

Journal of the American Academy of Dermatology

Sensitivity of Personalized Circulating Tumor DNA Assay in Advanced Cutaneous Squamous Cell Carcinoma

Kim EY, Ruiz ES, Hanna GJ, Thakuria M, Silk AW


 

Journal of Cancer Survivorship

Cancer Survivorship Programs at the Dana-Farber Cancer Institute

Partridge AH, Morgans A, Knelson LP, Recklitis C, Nekhlyudov L, Chi SN, Kenney LB, Diller L, Vrooman LM


 

Journal of Cancer Survivorship

Online Description of Services Provided in Adult Survivorship Programs Across U.S. Accredited Cancer Centers

Contreras-Chavez P, Nekhlyudov L


 

Journal of Clinical Investigation

HER2 Heterogeneity and Treatment Response-Associated Profiles in HER2-Positive Breast Cancer in the NCT02326974 Clinical Trial

Li Z, Metzger Filho O, Goyette MA, Kamat A, Spring LM, Waks AG, King TA, Lester SC, Bellon JR, Polyak K


 

Journal of Nuclear Medicine

The Current and Future Roles of Precision Oncology in Advanced Breast Cancer

Jacene H


 

Journal of Palliative Medicine

Bolstering Advance Care Planning Measurement Using Natural Language Processing

Zupanc SN, Durieux BN, Lindvall C


 

Journal of Thoracic Oncology

Real-World Genomic Profile of EGFR Second-Site Mutations and Other Osimertinib Resistance Mechanisms and Clinical Landscape of NSCLC Post-Osimertinib

Rotow JK, Jänne PA


 

JCO Oncology Practice

Hematology and Oncology Fellow Education About Sexual and Reproductive Health: A Survey of Program Directors in the United States

Bober SL


 

JCO Oncology Practice

Optimization of Advanced Molecular Genetic Testing Utilization in Hematopathology: A Goldilocks Approach to Bone Marrow Testing

AlJabban A, Paik H, Aster JC, Berliner N, Brouillard J, Brown JR, Burns KH, Castillo JJ, Card J, Dal Cin P, DeAngelo DJ, Dorfman DM, Ebert BL, Garcia JS, Jacobson CA, Lakhani H, Laubach JP, Ligon AH, Lindsley RC, Lovitch SB, Luskin MR, Morgan EA, Petrides A, Pinkus GS, Pozdnyakova O, Stone RM, Winer ES, Kim AS


 

JCO Oncology Practice

When Cancer Centers Snooze, Patients Lose: It is Time to Make Insomnia a Priority for Survivors

Zhou ES, Recklitis CJ, Partridge AH


 

Medical Physics

MV-based Relative Electron Density Estimation (iMREDe) for MR-LINAC Dose Calculation

Myronakis M, Hu YH, Jacobson MW, Williams CL, Berbeco RI


 

Molecular Therapy

An Empowered, Clinically Viable Hematopoietic Stem Cell Gene Therapy for the Treatment of Multisystemic Mucopolysaccharidosis Type II

Das S, Montepeloso A, Patel J, Cavalca E, Ferro F


 

Nanoscale

AGuIX Nanoparticle-Nanobody Bioconjugates to Target Immune Checkpoint Receptors

Seban L, Muradova Z, Crowley S, Bello E, Dougan M, Schoenfeld JD, Brown N, Berbeco R


 

Nature Reviews Cancer

Targeting Cancer Cell Dormancy

Agudo J


 

Nature Reviews Clinical Oncology

Lung Cancer in Patients Who Have Never Smoked - An Emerging Disease

LoPiccolo J, Gusev A, Christiani DC, Jänne PA


 

Oncogene

Genetically-Engineered Mouse Models of Small Cell Lung Cancer: The Next Generation

Oser MG


 

Oncologist

Impact of Increasing PD-L1 Levels on Outcomes to PD-1/PD-L1 Inhibition in Patients With NSCLC: A Pooled Analysis of 11 Prospective Clinical Trials

Ricciuti B, Awad MM


 

Oncologist

Patient-Reported Outcomes in KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma

Choueiri TK


 

Oncologist

The 5th Kidney Cancer Research Summit: Research Accelerating Cures for Renal Cell Carcinoma in 2023

Choueiri TK, Pels K


 

Otolaryngology-Head and Neck Surgery

Personal Social Networks and Care-Seeking for Head and Neck Cancer: A Qualitative Study

Batool S, Hansen EE, Sethi RKV, Rettig EM, Goguen LA, Annino D, Uppaluri R, Faden DL, Dohan D, Dhand A, Reich AJ, Bergmark RW


 

PLoS Biology

Tracing the Evolutionary Origins of Antiviral Immunity

Kranzusch PJ


 

Psycho-Oncology

Gratitude, Optimism, and Satisfaction with Life and Patient-Reported Outcomes in Patients Undergoing Hematopoietic Stem Cell Transplantation

Amonoo HL, Daskalakis E, Deary EC, Guo M, Boardman AC, Keane EP, Lam JA, Newcomb RA, Onyeaka HK, Huffman JC, El-Jawahri A


 

Psycho-Oncology

Pain Coping, Multidisciplinary Care, and mHealth: Patients' Views on Managing Advanced Cancer Pain

Beck M, Enzinger AC, Tulsky JA, Edwards RR, Schreiber KL, Azizoddin DR


 

Translational Behavioral Medicine

Developing a Culturally Tailored Digital Health Intervention for Insomnia in Black Women

Zhou ES, Revette A


 

Transplantation and Cellular Therapy

Opportunistic Infections in Patients Receiving Post-Transplantation Cyclophosphamide: Impact of Haploidentical versus Unrelated Donor Allograft

Little JS, Duléry R, Shapiro RM, Aleissa MM, Prockop SE, Koreth J, Ritz J, Antin JH, Cutler C, Nikiforow S, Romee R, Issa NC, Ho VT, Baden LR, Soiffer RJ, Gooptu M


 

Trends in Cell Biology

The Bidirectional Relationship Between Metabolism and Cell Cycle Control

Vander Heiden MG